Generate Biomedicines, Inc. GENB

About Generate Biomedicines, Inc. (GENB): stock profile, AI score and financials

Generate Biomedicines, Inc. (GENB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. GENB is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Generate Biomedicines, Inc. reports quarterly revenue of $6.3M, net income of $-67.3M, free cash flow of $-58.9M. Top institutional holders of GENB by reported 13-F value include Flagship Pioneering, FMR, Capital World Investors, based on the most recent SEC filings. GENB trades on the Nasdaq exchange and files with the SEC under CIK 2100782. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GENB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Generate Biomedicines, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 2100782 →